sorafenib has been researched along with Carcinoma, Papillary in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (28.57) | 29.6817 |
| 2010's | 20 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM | 1 |
| Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB | 1 |
| Ewig, JM; Iyer, P; Mayer, JL | 1 |
| Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H | 1 |
| Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Pitoia, F | 1 |
| Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK | 1 |
| Chen, L; Dong, Q; Liu, M; Ruan, M | 1 |
| Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F | 1 |
| Ahn, SH; Clayman, GL; Henderson, YC; Kang, Y | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Clayman, GL; Herzog, CE; Sherman, SI; Waguespack, SG; Williams, MD | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Fagin, JA; Pfister, DG; Tuttle, RM | 1 |
| Bernardini, R; Duntas, LH | 1 |
| Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R | 1 |
| Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L | 1 |
| Geliebter, J; Moscatello, AL; Nowicki, TS; Schantz, S; Shin, E; Tiwari, RK | 1 |
| Aguillo Gutiérrez, E; Altemir Trallero, J; Cabrejas Gómez, Mdel C; Lázaro Sierra, J; Ocón Bretón, J | 1 |
| Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS | 1 |
| Fuziwara, CS; Hirokawa, M; Matsuse, M; Mitsutake, N; Miyauchi, A; Nishihara, E; Ogi, T; Saenko, VA; Suzuki, K; Tanimura, S; Yamashita, S | 1 |
| Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW | 1 |
| Cohen, MS; Cohen, SM; Mukerji, R; Samadi, AK; Timmermann, BN | 1 |
| Fagin, JA | 1 |
| Carlomagno, F; De Falco, V; Melillo, RM; Nappi, TC; Pepe, S; Salerno, P; Salvatore, G; Santoro, M; Troncone, G; Wilhelm, SM | 1 |
| Bukowski, RM; Choueiri, TK; Elson, P; Escudier, B; Negrier, S; Oudard, S; Plantade, A; Ravaud, A; Rini, BI; Zhou, M | 1 |
| Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E | 1 |
5 review(s) available for sorafenib and Carcinoma, Papillary
| Article | Year |
|---|---|
Sorafenib and thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Mutation; Niacinamide; Oncogenes; Phenylurea Compounds; Phosphotransferases; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms | 2004 |
4 trial(s) available for sorafenib and Carcinoma, Papillary
| Article | Year |
|---|---|
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Dyspnea; Fatigue; Female; Humans; Hypertension; Hypocalcemia; Incidence; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Weight Loss | 2015 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2011 |
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Carcinoma, Papillary, Follicular; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
20 other study(ies) available for sorafenib and Carcinoma, Papillary
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2018 |
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Artery Obstruction; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2014 |
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Iodide Peroxidase; Iron-Binding Proteins; Microfilament Proteins; Muscle Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Thyrotropin; Signal Transduction; Sorafenib; Symporters; Thyroid Neoplasms | 2015 |
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2008 |
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Topics: Adolescent; Benzenesulfonates; Carcinoma, Papillary; Child; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2009 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms | 2010 |
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outcome; Humans; Imatinib Mesylate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiography; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2011 |
The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms; Urokinase-Type Plasminogen Activator | 2011 |
[Long-standing differentiated thyroid carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillary; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Diagnostic Errors; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Niacinamide; Palliative Care; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Tuberculosis, Miliary | 2012 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; COS Cells; DNA, Neoplasm; Humans; Mice; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Withanolides | 2012 |
BRAF is a therapeutic target in aggressive thyroid carcinoma.
Topics: Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Transplantation, Heterologous | 2006 |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate | 2007 |